236 related articles for article (PubMed ID: 15287095)
1. Effect of permixon on human prostate cell growth: lack of apoptotic action.
Hill B; Kyprianou N
Prostate; 2004 Sep; 61(1):73-80. PubMed ID: 15287095
[TBL] [Abstract][Full Text] [Related]
2. Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression.
Habib FK; Ross M; Ho CK; Lyons V; Chapman K
Int J Cancer; 2005 Mar; 114(2):190-4. PubMed ID: 15543614
[TBL] [Abstract][Full Text] [Related]
3. Serenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPH.
Bayne CW; Donnelly F; Ross M; Habib FK
Prostate; 1999 Sep; 40(4):232-41. PubMed ID: 10420151
[TBL] [Abstract][Full Text] [Related]
4. A preliminary investigation of the enzymatic inhibition of 5alpha-reduction and growth of prostatic carcinoma cell line LNCap-FGC by natural astaxanthin and Saw Palmetto lipid extract in vitro.
Anderson ML
J Herb Pharmacother; 2005; 5(1):17-26. PubMed ID: 16093232
[TBL] [Abstract][Full Text] [Related]
5. The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate.
Bayne CW; Ross M; Donnelly F; Habib FK
J Urol; 2000 Sep; 164(3 Pt 1):876-81. PubMed ID: 10953171
[TBL] [Abstract][Full Text] [Related]
6. Effects of the lipidosterolic extract of Serenoa repens (Permixon) on human prostatic cell lines.
Ravenna L; Di Silverio F; Russo MA; Salvatori L; Morgante E; Morrone S; Cardillo MR; Russo A; Frati L; Gulino A; Petrangeli E
Prostate; 1996 Oct; 29(4):219-30. PubMed ID: 8876705
[TBL] [Abstract][Full Text] [Related]
7. Effects of dietary saw palmetto on the prostate of transgenic adenocarcinoma of the mouse prostate model (TRAMP).
Wadsworth TL; Worstell TR; Greenberg NM; Roselli CE
Prostate; 2007 May; 67(6):661-73. PubMed ID: 17342743
[TBL] [Abstract][Full Text] [Related]
8. Anti-inflammatory properties of Lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia.
Bernichtein S; Pigat N; Camparo P; Latil A; Viltard M; Friedlander G; Goffin V
Prostate; 2015 May; 75(7):706-22. PubMed ID: 25683150
[TBL] [Abstract][Full Text] [Related]
9. Induction of apoptosis and inhibition of cell proliferation by the lipido-sterolic extract of Serenoa repens (LSESr, Permixon in benign prostatic hyperplasia.
Vacherot F; Azzouz M; Gil-Diez-De-Medina S; Colombel M; De La Taille A; Lefrère Belda MA; Abbou CC; Raynaud JP; Chopin DK
Prostate; 2000 Nov; 45(3):259-66. PubMed ID: 11074529
[TBL] [Abstract][Full Text] [Related]
10. Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia.
Di Silverio F; Monti S; Sciarra A; Varasano PA; Martini C; Lanzara S; D'Eramo G; Di Nicola S; Toscano V
Prostate; 1998 Oct; 37(2):77-83. PubMed ID: 9759701
[TBL] [Abstract][Full Text] [Related]
11. Saw Palmetto induces growth arrest and apoptosis of androgen-dependent prostate cancer LNCaP cells via inactivation of STAT 3 and androgen receptor signaling.
Yang Y; Ikezoe T; Zheng Z; Taguchi H; Koeffler HP; Zhu WG
Int J Oncol; 2007 Sep; 31(3):593-600. PubMed ID: 17671686
[TBL] [Abstract][Full Text] [Related]
12. Potency of a novel saw palmetto ethanol extract, SPET-085, for inhibition of 5alpha-reductase II.
Pais P
Adv Ther; 2010 Aug; 27(8):555-63. PubMed ID: 20623347
[TBL] [Abstract][Full Text] [Related]
13. Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies.
Paubert-Braquet M; Cousse H; Raynaud JP; Mencia-Huerta JM; Braquet P
Eur Urol; 1998; 33(3):340-7. PubMed ID: 9555564
[TBL] [Abstract][Full Text] [Related]
14. Lipido-sterolic extract of Serenoa repens (LSESr, Permixon) treatment affects human prostate cancer cell membrane organization.
Petrangeli E; Lenti L; Buchetti B; Chinzari P; Sale P; Salvatori L; Ravenna L; Lococo E; Morgante E; Russo A; Frati L; Di Silverio F; Russo MA
J Cell Physiol; 2009 Apr; 219(1):69-76. PubMed ID: 19067321
[TBL] [Abstract][Full Text] [Related]
15. Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action.
Buck AC
J Urol; 2004 Nov; 172(5 Pt 1):1792-9. PubMed ID: 15540722
[TBL] [Abstract][Full Text] [Related]
16. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study.
Debruyne F; Koch G; Boyle P; Da Silva FC; Gillenwater JG; Hamdy FC; Perrin P; Teillac P; Vela-Navarrete R; Raynaud JP
Eur Urol; 2002 May; 41(5):497-506; discussion 506-7. PubMed ID: 12074791
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: comparison with finasteride.
Van Coppenolle F; Le Bourhis X; Carpentier F; Delaby G; Cousse H; Raynaud JP; Dupouy JP; Prevarskaya N
Prostate; 2000 Apr; 43(1):49-58. PubMed ID: 10725865
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the DHT-induced PSA secretion by Verbascum xanthophoeniceum and Serenoa repens extracts in human LNCaP prostate epithelial cells.
Marcoccia D; Georgiev MI; Alipieva KI; Lorenzetti S
J Ethnopharmacol; 2014 Aug; 155(1):616-25. PubMed ID: 24928827
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride.
Zlotta AR; Teillac P; Raynaud JP; Schulman CC
Eur Urol; 2005 Aug; 48(2):269-76. PubMed ID: 15939527
[TBL] [Abstract][Full Text] [Related]
20. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients.
Carraro JC; Raynaud JP; Koch G; Chisholm GD; Di Silverio F; Teillac P; Da Silva FC; Cauquil J; Chopin DK; Hamdy FC; Hanus M; Hauri D; Kalinteris A; Marencak J; Perier A; Perrin P
Prostate; 1996 Oct; 29(4):231-40; discussion 241-2. PubMed ID: 8876706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]